Function of MiRNA-221/222 in Thyroid Cance_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 WANGYun-sheng ^1,2 , GAOQing-jun ¹ ,  ZHAODai-wei ³

1. Department of Thyroid Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, Guizhou Province, China;
2. Guizhou Medical University, Guiyang 550004, Guizhou Province, China;
3. Department of Thyroid Surgery, Second Affiliated Hospital of Guizhou Medical University, Kaili 556000, Guizhou Province, China;

Corresponding author：

ZHAODai-wei, Email: zhaodw@hotmail.com

Keywords：

Thyroid cancer; MiRNA; Tumor marker

DOI：

10.7507/1007-9424.20160232

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the domestic and abroad articles related to the research on the relation between miRNA-221/222 and thyroid cancer, and explore the important effects of miRNA-221/222 in diagnosis and treatment of thyroid cancer. Methods Domestic and international publications involving the relationship of miRNA-221/222 to thyroid cancer were screened and reviewed. Results MiRNA-221/222 is a tumor marker with high specificity and sensitivity in thyroid cancer. It has important significance for diagnosis, treatment and prognosis of thyroid cancer. Conclusion MiRNA-221/222 is not only related to diagnosis of thyroid cancer, but also have provided a new research direction and method for gene therapy of thyroid cancer．

Citation： WANGYun-sheng, GAOQing-jun, ZHAODai-wei. Function of MiRNA-221/222 in Thyroid Cance. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(7): 887-890. doi: 10.7507/1007-9424.20160232 Copy

1.	Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries. Chin J Cancer Res, 2013, 25(1): 10-21.
2.	Catalano MG, Fortunati N, Boccuzzi G. Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne), 2012, 3: 40.
3.	Caminha LS, Momesso DP, Vaisman F, et al. Longterm follow-up of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment. Clin Nucl Med, 2013, 38(10): 765-769.
4.	高明, 滕卫平, 刘永峰, 等.甲状腺结节和分化型甲状腺癌诊治指南.中国肿瘤临床, 2012, 39(17): 1249-1272.
5.	Sokilde R, Vincent M, Moller A K, et al. Efficient Identification of miRNAs for classification of tumor origin. J Mol Diagn, 2014, 16(1): 106-115.
6.	Tomasetti M, Santarelli L, Neuzil J, et al. MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion, 2014, 19 Pt A: 29-38.
7.	Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type. Thyroid, 2011, 21(2): 125-134.
8.	Waldman SA, Terzic A. MicroRNA signatures as diagnostic and therapeutic targets. Clin Chem, 2008, 54(6): 943-944.
9.	李丹, 郭丽英. microRNA与乳腺癌浸润转移关系的研究进展.中国普外基础与临床杂志, 2014, 21(5): 654-657.
10.	Braun J, Hüttelmaier S. Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res, 2011, 4 Suppl 1: S1.
11.	He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Prec Natl Acad Sci USA, 2005, 102(52): 19075-19080.
12.	Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Revi, 2015, 81: 75-93.
13.	杨良, 李航宇, 刘金钢. microRNA调控肿瘤微环境的研究进展.中国普外基础与临床杂志, 2015, 22(2): 251-255.
14.	Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med, 2014, 20(8): 460-469.
15.	Qiu T, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett, 2014, 588(7): 1168-1177.
16.	Brocato J, Chervona Y, Costa M. Molecular responses to hypoxia-inducible factor 1αand beyond. Mol Pharmacol, 2014, 85(5): 651-657.
17.	Tan SB, Li J, Chen X, et al. Small molecule inhibitor of myogenic microRNAs leads to a discovery of miR-221/222-myoD-myomiRs regulatory pathway. Chem Biol, 2014, 21(10): 1265-1270.
18.	Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett, 2014, 588(1): 99-104.
19.	Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer, 2013, 108(2): 361-369.
20.	姚廷敬, 彭德峰, 朱金海, 等.甲状腺癌miRNA-146与BRAF突变的相关性研究.淮海医药, 2013, 31(3): 189-191.
21.	Eszlinger M, Krogdahl A, Münz S, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid, 2014, 24(2): 305-313.
22.	Mazeh H, Levy Y, Mizrahi I, et al. Differentiating benign from mali-gnant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J Sur Res, 2013, 180(2): 216-221.
23.	陈晓敏, 曹国平, 陈琪. miR-221及miR-222在甲状腺结节针吸细胞活检组织中的表达水平.现代实用医学, 2013, 25(10): 1120-1122.
24.	Pai R, Nehru GA, Samuel P, et al. Discriminating thyroid cancers from benign lesions based on differential expression of a limited set of miRNA using paraffin embedded tissues. Indian J Pathol Microbiol, 2012, 55(2): 158-162.
25.	刘超, 戴璇璇, 周毅力, 等.甲状腺乳头状癌mir-221表达与BRAF突变的相关性研究.中国肿瘤, 2012, 21(4): 298-302.
26.	Visone R, Russo L, Pallante P, et al. MicroRNAs(miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
27.	Lee JC, Zhao JT, Gundara J, et al. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222 Original Research Article. J Surg Res, 2015, 196(1): 39-48.
28.	Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer, 2006, 13(2): 497-508.
29.	Wojtas B, Ferraz C, Stokowy T, et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol, 2014, 388(1-2): 1-9.
30.	Ihle MA, Trautmann M, Kuenstlinger H, et al. miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Mol Oncol, 2015, 9(7): 1421-1433.
31.	Visone R, Russo L, Pallante P, et al. MicroRNAs(miR)-221and miR-222, both over expressed in human thyroid papillary carcinomas, regulate p27Kip1 proteinlevels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
32.	Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16(6): 498-509.
33.	张春智, 康春生, 浦佩玉, 等.反义microRNA-221与反义microRNA-222抑制人脑胶质瘤细胞的体外与体内生长.中华肿瘤杂志, 2009, 31(10): 721-726.
34.	Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA21 concentrations in early and advanced breast cancer. Clin Chem, 2011, 57(1): 84-91.
35.	Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genomewide serum microRNA expression profiling predict survival of non small cell lung cancer. Clin Oncol, 2010, 28(10): 1721-1726.

1. Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries. Chin J Cancer Res, 2013, 25(1): 10-21.
2. Catalano MG, Fortunati N, Boccuzzi G. Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne), 2012, 3: 40.
3. Caminha LS, Momesso DP, Vaisman F, et al. Longterm follow-up of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment. Clin Nucl Med, 2013, 38(10): 765-769.
4. 高明, 滕卫平, 刘永峰, 等.甲状腺结节和分化型甲状腺癌诊治指南.中国肿瘤临床, 2012, 39(17): 1249-1272.
5. Sokilde R, Vincent M, Moller A K, et al. Efficient Identification of miRNAs for classification of tumor origin. J Mol Diagn, 2014, 16(1): 106-115.
6. Tomasetti M, Santarelli L, Neuzil J, et al. MicroRNA regulation of cancer metabolism: role in tumour suppression. Mitochondrion, 2014, 19 Pt A: 29-38.
7. Aschebrook-Kilfoy B, Ward MH, Sabra MM, et al. Thyroid cancer incidence patterns in the United States by histologic type. Thyroid, 2011, 21(2): 125-134.
8. Waldman SA, Terzic A. MicroRNA signatures as diagnostic and therapeutic targets. Clin Chem, 2008, 54(6): 943-944.
9. 李丹, 郭丽英. microRNA与乳腺癌浸润转移关系的研究进展.中国普外基础与临床杂志, 2014, 21(5): 654-657.
10. Braun J, Hüttelmaier S. Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin. Thyroid Res, 2011, 4 Suppl 1: S1.
11. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Prec Natl Acad Sci USA, 2005, 102(52): 19075-19080.
12. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Revi, 2015, 81: 75-93.
13. 杨良, 李航宇, 刘金钢. microRNA调控肿瘤微环境的研究进展.中国普外基础与临床杂志, 2015, 22(2): 251-255.
14. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med, 2014, 20(8): 460-469.
15. Qiu T, Zhou X, Wang J, et al. MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett, 2014, 588(7): 1168-1177.
16. Brocato J, Chervona Y, Costa M. Molecular responses to hypoxia-inducible factor 1αand beyond. Mol Pharmacol, 2014, 85(5): 651-657.
17. Tan SB, Li J, Chen X, et al. Small molecule inhibitor of myogenic microRNAs leads to a discovery of miR-221/222-myoD-myomiRs regulatory pathway. Chem Biol, 2014, 21(10): 1265-1270.
18. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett, 2014, 588(1): 99-104.
19. Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer, 2013, 108(2): 361-369.
20. 姚廷敬, 彭德峰, 朱金海, 等.甲状腺癌miRNA-146与BRAF突变的相关性研究.淮海医药, 2013, 31(3): 189-191.
21. Eszlinger M, Krogdahl A, Münz S, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid, 2014, 24(2): 305-313.
22. Mazeh H, Levy Y, Mizrahi I, et al. Differentiating benign from mali-gnant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J Sur Res, 2013, 180(2): 216-221.
23. 陈晓敏, 曹国平, 陈琪. miR-221及miR-222在甲状腺结节针吸细胞活检组织中的表达水平.现代实用医学, 2013, 25(10): 1120-1122.
24. Pai R, Nehru GA, Samuel P, et al. Discriminating thyroid cancers from benign lesions based on differential expression of a limited set of miRNA using paraffin embedded tissues. Indian J Pathol Microbiol, 2012, 55(2): 158-162.
25. 刘超, 戴璇璇, 周毅力, 等.甲状腺乳头状癌mir-221表达与BRAF突变的相关性研究.中国肿瘤, 2012, 21(4): 298-302.
26. Visone R, Russo L, Pallante P, et al. MicroRNAs(miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
27. Lee JC, Zhao JT, Gundara J, et al. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222 Original Research Article. J Surg Res, 2015, 196(1): 39-48.
28. Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer, 2006, 13(2): 497-508.
29. Wojtas B, Ferraz C, Stokowy T, et al. Differential miRNA expression defines migration and reduced apoptosis in follicular thyroid carcinomas. Mol Cell Endocrinol, 2014, 388(1-2): 1-9.
30. Ihle MA, Trautmann M, Kuenstlinger H, et al. miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Mol Oncol, 2015, 9(7): 1421-1433.
31. Visone R, Russo L, Pallante P, et al. MicroRNAs(miR)-221and miR-222, both over expressed in human thyroid papillary carcinomas, regulate p27Kip1 proteinlevels and cell cycle. Endocr Relat Cancer, 2007, 14(3): 791-798.
32. Garofalo M, Di Leva G, Romano G, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16(6): 498-509.
33. 张春智, 康春生, 浦佩玉, 等.反义microRNA-221与反义microRNA-222抑制人脑胶质瘤细胞的体外与体内生长.中华肿瘤杂志, 2009, 31(10): 721-726.
34. Asaga S, Kuo C, Nguyen T, et al. Direct serum assay for microRNA21 concentrations in early and advanced breast cancer. Clin Chem, 2011, 57(1): 84-91.
35. Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genomewide serum microRNA expression profiling predict survival of non small cell lung cancer. Clin Oncol, 2010, 28(10): 1721-1726.

Previous Article
空肠胃逆行性套叠1例报道
Next Article
Research Progress of Sentinel Lymph Node Biopsy in the Surgery of Thyroid Carcinoma

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Function of MiRNA-221/222 in Thyroid Cance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content